Trial · NCT02746991

Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis

NCT02746991, Phase 3, Completed, EyePoint Pharmaceuticals, Inc.; results first posted 2020-07-07

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis. Trials, record NCT02746991. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02746991

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis
NCT number: NCT02746991
Status: Completed
Phases: Phase 3
Enrollment: 153 participants, actual
Lead sponsor: EyePoint Pharmaceuticals, Inc.
Conditions: Posterior Uveitis, Intermediate Uveitis, Panuveitis
Interventions: Sham Injection, FAI Insert
First posted: 2016-04-21
Last updated: 2020-07-21
Results first posted: 2020-07-07

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months	6 Months	Proportion of Subjects with Recurrence of Uveitis in the Study Eye within 6 Months Including Reason for Imputed Recurrence (ITT Population)
Secondary	Number of Participants With Recurrence of Uveitis in Study Eye Within 36 Months	36 Months	Proportion of Subjects with Recurrence of Uveitis in the Study Eye at 36 Months Including Reason for Imputed Recurrence (ITT Population)

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months	6 Months	Proportion of Subjects with Recurrence of Uveitis in the Study Eye within 6 Months Including Reason for Imputed Recurrence (ITT Population)	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Recurrence of Uveitis in Study Eye Within 36 Months	36 Months	Proportion of Subjects with Recurrence of Uveitis in the Study Eye at 36 Months Including Reason for Imputed Recurrence (ITT Population)	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months	Sham Injection	28	Participants
Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months	FAI Insert	22	Participants
Number of Participants With Recurrence of Uveitis in Study Eye Within 36 Months	Sham Injection	39	Participants
Number of Participants With Recurrence of Uveitis in Study Eye Within 36 Months	FAI Insert	47	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Sham Injection	52
Overall Study	STARTED	FAI Insert	101
Overall Study	COMPLETED	Sham Injection	24
Overall Study	COMPLETED	FAI Insert	67
Overall Study	NOT COMPLETED	Sham Injection	28
Overall Study	NOT COMPLETED	FAI Insert	34

Source ClinicalTrials.gov

Adverse events176

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anterior chamber cell	Eye disorders	Sham Injection	7	52
other	Anterior chamber cell	Eye disorders	FAI Insert	10	101
other	Cataract	Eye disorders	Sham Injection	10	52
other	Cataract	Eye disorders	FAI Insert	17	101
other	Cataract subcapsular	Eye disorders	Sham Injection	9	52
other	Cataract subcapsular	Eye disorders	FAI Insert	36	101
other	Conjunctival haemorrhage	Eye disorders	Sham Injection	1	52
other	Conjunctival haemorrhage	Eye disorders	FAI Insert	6	101
other	Cystoid macular oedema	Eye disorders	Sham Injection	8	52
other	Cystoid macular oedema	Eye disorders	FAI Insert	4	101

1 to 10 of 176Source ClinicalTrials.gov

See all 176 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Sham Injection	0	52
Total, all-cause mortality	FAI Insert	0	101
Total, other adverse events	Sham Injection	49	52
Total, other adverse events	FAI Insert	94	101
Total, serious adverse events	Sham Injection	7	52
Total, serious adverse events	FAI Insert	21	101

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
38027419	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
FAI Insert vs Sham Injection: Number of Participants With Recurrence of Uveitis in Study Eye Within 36 Months	Trial comparisons
FAI Insert vs Sham Injection: Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months	Trial comparisons
FAI Insert vs Sham Injection: deaths from any cause	Trial comparisons
FAI Insert vs Sham Injection: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02746991

GET https://conductscience.org/api/trials/v1/NCT02746991/events?page=2

API reference For AI assistants